Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine Rentosertib represents a novel mechanism, novel AI-identified target, and novel AI-empowered molecule emerging from Insilico's aging-biology-driven Pharma.AI platform The GENESIS-IPF Phase IIa study showed manageable safety and tolerability, wit

July 7, 2026 -- Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this agreement AstraZeneca will gain access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. GenoSphere cohorts consist of comprehensive Exome+® genomic and rich longitudinal clinical data, designed to accelerate Life Sciences research across the development cycle. The

July 7, 2026 -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed financing round led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio and existing investor SFC Capital. Proceeds will support pre-clinical development, manufacturing scale-up, regulatory engagement with the MHRA and FDA, and progression toward first-in-h

Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population July 07, 2026 -- Spur Therapeutics today announced that the first patient has been dosed in GALILEO-3, its Phase 3 pivotal clinical trial evaluating avigbagene parvec (FLT201), an investigational gene therapy for Gaucher disease type 1 (GD1). The trial will assess the safety and efficacy of FLT201 in adults currently on stable standard-of-care therapies.

– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – July 07, 2026 -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to d

Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimus July 7, 2026 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the publication of its primary result analysis of the Phase 3 COMPETE trial in The Lancet. The clinical data demonstrated that non-carrier-added (n.c.a.) 177Lu-edotreotide (also known as 177Lu-edotreotide or ITM-11) signific

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas July 1, 2026 -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas. The collaboration is designed to identify clinically differentiated drug candidates for pr

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients July 06, 2026 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-label trial designed to evaluate the e

First ever APRIL inhibitor to demonstrate statistically significant eGFR stabilization with evidence of improvement versus placebo over two years, highlighting VOYXACT's promising ability to provide long-term kidney protection and enhance clinical outcomes in IgAN VOYXACT showed robust reductions in risk of progression to kidney failure, reinforcing the therapeutic potential of selectively blocking APRIL VOYXACT® received U.S. FDA accelerated approval for reduction in proteinuria in adults wit

The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher program. The FDA has approved a pediatric expansion of Vertex Pharmaceuticals’ gene therapy Casgevy, allowing its use in children 2 years and up who have sickle cell disease and transfusion-dependent beta thalassemia. Casgevy is the first genetic medicine for these indications that can be used in yo